However, a phase III trial (COTEZO) evaluating the combination of atezolizumab and MEK inhibitor cobimetinib versus atezolizumab alone or regorafenib in patients with chemo-refractory CRC did not meet its primary endpoint, showing no significant difference in PFS or ORR between the treatment arms (228). Here, MAP2K7 is linked to colorectal carcinoma.